BIOMAT Database Logo BIOMAT Database Logo

Cost-Effectiveness of Magnetic Resonance Imaging Screening for Women With Extremely Dense Breast Tissue. 2021

H Amarens Geuzinge, and Marije F Bakker, and Eveline A M Heijnsdijk, and Nicolien T van Ravesteyn, and Wouter B Veldhuis, and Ruud M Pijnappel, and Stéphanie V de Lange, and Marleen J Emaus, and Ritse M Mann, and Evelyn M Monninkhof, and Petra K de Koekkoek-Doll, and Carla H van Gils, and Harry J de Koning, and
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.

Extremely dense breast tissue is associated with increased breast cancer risk and limited sensitivity of mammography. The DENSE trial showed that additional magnetic resonance imaging (MRI) screening in women with extremely dense breasts resulted in a substantial reduction in interval cancers. The cost-effectiveness of MRI screening for these women is unknown. We used the MISCAN-breast microsimulation model to simulate several screening protocols containing mammography and/or MRI to estimate long-term effects and costs. The model was calibrated using results of the DENSE trial and adjusted to incorporate decreases in breast density with increasing age. Screening strategies varied in the number of MRIs and mammograms offered to women ages 50-75 years. Outcomes were numbers of breast cancers, life-years, quality-adjusted life-years (QALYs), breast cancer deaths, and overdiagnosis. Incremental cost-effectiveness ratios (ICERs) were calculated (3% discounting), with a willingness-to-pay threshold of €22 000. Calibration resulted in a conservative fit of the model regarding MRI detection. Both strategies of the DENSE trial were dominated (biennial mammography; biennial mammography plus MRI). MRI alone every 4 years was cost-effective with €15 620 per QALY. Screening every 3 years with MRI alone resulted in an incremental cost-effectiveness ratio of €37 181 per QALY. All strategies with mammography and/or a 2-year interval were dominated because other strategies resulted in more additional QALYs per additional euro. Alternating mammography and MRI every 2 years was close to the efficiency frontier. MRI screening is cost-effective for women with extremely dense breasts, when applied at a 4-year interval. For a willingness to pay more than €22 000 per QALY gained, MRI at a 3-year interval is cost-effective as well.

UI MeSH Term Description Entries
D008279 Magnetic Resonance Imaging Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques. Chemical Shift Imaging,MR Tomography,MRI Scans,MRI, Functional,Magnetic Resonance Image,Magnetic Resonance Imaging, Functional,Magnetization Transfer Contrast Imaging,NMR Imaging,NMR Tomography,Tomography, NMR,Tomography, Proton Spin,fMRI,Functional Magnetic Resonance Imaging,Imaging, Chemical Shift,Proton Spin Tomography,Spin Echo Imaging,Steady-State Free Precession MRI,Tomography, MR,Zeugmatography,Chemical Shift Imagings,Echo Imaging, Spin,Echo Imagings, Spin,Functional MRI,Functional MRIs,Image, Magnetic Resonance,Imaging, Magnetic Resonance,Imaging, NMR,Imaging, Spin Echo,Imagings, Chemical Shift,Imagings, Spin Echo,MRI Scan,MRIs, Functional,Magnetic Resonance Images,Resonance Image, Magnetic,Scan, MRI,Scans, MRI,Shift Imaging, Chemical,Shift Imagings, Chemical,Spin Echo Imagings,Steady State Free Precession MRI
D008327 Mammography Radiographic examination of the breast. 3D-Mammography,Digital Breast Tomosynthesis,Digital Mammography,X-ray Breast Tomosynthesis,3D Mammography,3D-Mammographies,Breast Tomosyntheses, Digital,Breast Tomosyntheses, X-ray,Breast Tomosynthesis, Digital,Breast Tomosynthesis, X-ray,Digital Breast Tomosyntheses,Digital Mammographies,Mammographies,Mammographies, Digital,Mammography, Digital,X ray Breast Tomosynthesis,X-ray Breast Tomosyntheses
D008403 Mass Screening Organized periodic procedures performed on large groups of people for the purpose of detecting disease. Screening,Mass Screenings,Screening, Mass,Screenings,Screenings, Mass
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071060 Breast Density Measurement of relative composition of different BREAST tissue types often determined from MAMMOGRAPHY; ULTRASONOGRAPHY; or MRI. Mammographic Breast Density,Mammographic Density,Breast Densities,Breast Densities, Mammographic,Breast Density, Mammographic,Density, Mammographic,Mammographic Breast Densities,Mammographic Densities

Related Publications

H Amarens Geuzinge, and Marije F Bakker, and Eveline A M Heijnsdijk, and Nicolien T van Ravesteyn, and Wouter B Veldhuis, and Ruud M Pijnappel, and Stéphanie V de Lange, and Marleen J Emaus, and Ritse M Mann, and Evelyn M Monninkhof, and Petra K de Koekkoek-Doll, and Carla H van Gils, and Harry J de Koning, and
Comment on: Cost-effectiveness of magnetic resonance imaging screening for women with extremely DENSE breast tissue.
April 2022, European journal of radiology,
H Amarens Geuzinge, and Marije F Bakker, and Eveline A M Heijnsdijk, and Nicolien T van Ravesteyn, and Wouter B Veldhuis, and Ruud M Pijnappel, and Stéphanie V de Lange, and Marleen J Emaus, and Ritse M Mann, and Evelyn M Monninkhof, and Petra K de Koekkoek-Doll, and Carla H van Gils, and Harry J de Koning, and
Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
September 2013, Journal of the National Cancer Institute,
H Amarens Geuzinge, and Marije F Bakker, and Eveline A M Heijnsdijk, and Nicolien T van Ravesteyn, and Wouter B Veldhuis, and Ruud M Pijnappel, and Stéphanie V de Lange, and Marleen J Emaus, and Ritse M Mann, and Evelyn M Monninkhof, and Petra K de Koekkoek-Doll, and Carla H van Gils, and Harry J de Koning, and
Supplemental MRI Screening for Women with Extremely Dense Breast Tissue.
November 2019, The New England journal of medicine,
H Amarens Geuzinge, and Marije F Bakker, and Eveline A M Heijnsdijk, and Nicolien T van Ravesteyn, and Wouter B Veldhuis, and Ruud M Pijnappel, and Stéphanie V de Lange, and Marleen J Emaus, and Ritse M Mann, and Evelyn M Monninkhof, and Petra K de Koekkoek-Doll, and Carla H van Gils, and Harry J de Koning, and
Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
September 2020, JAMA oncology,
H Amarens Geuzinge, and Marije F Bakker, and Eveline A M Heijnsdijk, and Nicolien T van Ravesteyn, and Wouter B Veldhuis, and Ruud M Pijnappel, and Stéphanie V de Lange, and Marleen J Emaus, and Ritse M Mann, and Evelyn M Monninkhof, and Petra K de Koekkoek-Doll, and Carla H van Gils, and Harry J de Koning, and
Beyond the AJR: "Cost-Effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk".
July 2021, AJR. American journal of roentgenology,
H Amarens Geuzinge, and Marije F Bakker, and Eveline A M Heijnsdijk, and Nicolien T van Ravesteyn, and Wouter B Veldhuis, and Ruud M Pijnappel, and Stéphanie V de Lange, and Marleen J Emaus, and Ritse M Mann, and Evelyn M Monninkhof, and Petra K de Koekkoek-Doll, and Carla H van Gils, and Harry J de Koning, and
Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
May 2006, JAMA,
H Amarens Geuzinge, and Marije F Bakker, and Eveline A M Heijnsdijk, and Nicolien T van Ravesteyn, and Wouter B Veldhuis, and Ruud M Pijnappel, and Stéphanie V de Lange, and Marleen J Emaus, and Ritse M Mann, and Evelyn M Monninkhof, and Petra K de Koekkoek-Doll, and Carla H van Gils, and Harry J de Koning, and
Application of Abbreviated Protocol of Magnetic Resonance Imaging for Breast Cancer Screening in Dense Breast Tissue.
March 2017, Academic radiology,
H Amarens Geuzinge, and Marije F Bakker, and Eveline A M Heijnsdijk, and Nicolien T van Ravesteyn, and Wouter B Veldhuis, and Ruud M Pijnappel, and Stéphanie V de Lange, and Marleen J Emaus, and Ritse M Mann, and Evelyn M Monninkhof, and Petra K de Koekkoek-Doll, and Carla H van Gils, and Harry J de Koning, and
Abbreviated Breast Magnetic Resonance Imaging for Supplemental Screening of Women With Dense Breasts and Average Risk.
November 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
H Amarens Geuzinge, and Marije F Bakker, and Eveline A M Heijnsdijk, and Nicolien T van Ravesteyn, and Wouter B Veldhuis, and Ruud M Pijnappel, and Stéphanie V de Lange, and Marleen J Emaus, and Ritse M Mann, and Evelyn M Monninkhof, and Petra K de Koekkoek-Doll, and Carla H van Gils, and Harry J de Koning, and
Cost-Effectiveness of MR-Mammography in Breast Cancer Screening of Women With Extremely Dense Breasts After Two Rounds of Screening.
January 2021, Frontiers in oncology,
H Amarens Geuzinge, and Marije F Bakker, and Eveline A M Heijnsdijk, and Nicolien T van Ravesteyn, and Wouter B Veldhuis, and Ruud M Pijnappel, and Stéphanie V de Lange, and Marleen J Emaus, and Ritse M Mann, and Evelyn M Monninkhof, and Petra K de Koekkoek-Doll, and Carla H van Gils, and Harry J de Koning, and
Supplemental Breast Cancer Screening With Molecular Breast Imaging for Women With Dense Breast Tissue.
August 2016, AJR. American journal of roentgenology,
Copied contents to your clipboard!